Dual efficacy of delta opioid receptor-selective ligands for ethanol drinking and anxiety

Journal of Pharmacology and Experimental Therapeutics

Volumn 335, Issue 1, 2010, Pages 133-139

  Van Rijn, Richard M ^a   Brissett, Daniela I ^a   Whistler, Jennifer L ^a  

^a UNIVERSITY OF CALIFORNIA SAN FRANCISCO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,4,4A,5,12,12AALPHA OCTAHYDRO 4AALPHA (3 HYDROXYPHENYL) 2 METHYLQUINOLINO[2,3 G]ISOQUINOLINE; 4 [ALPHA (4 ALLYL 2,5 DIMETHYL 1 PIPERAZINYL) 3 METHOXYBENZYL] N,N DIETHYLBENZAMIDE; ANXIOLYTIC AGENT; DELTA OPIATE RECEPTOR; DELTA OPIATE RECEPTOR AGONIST; DIAZEPAM; NALTREXONE; 4-(ALPHA-(4-ALLYL-2,5-DIMETHYL-1-PIPERAZINYL)-3-METHOXYBENZYL)-N,N-DIETHYLBENZAMIDE; BENZAMIDE DERIVATIVE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DRUGS USED IN THE TREATMENT OF ADDICTION; LIGAND; NARCOTIC ANTAGONIST; PIPERAZINE DERIVATIVE; QUINOLINE DERIVATIVE;

ALCOHOL CONSUMPTION; ALCOHOL WITHDRAWAL; ALCOHOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANXIETY DISORDER; ARTICLE; COMORBIDITY; CONTROLLED STUDY; DRINKING BEHAVIOR; DRUG EFFICACY; MALE; MAZE TEST; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RELAPSE; TREATMENT RESPONSE; AGONISTS; ANIMAL; ANIMAL BEHAVIOR; ANXIETY; C57BL MOUSE; DRUG EFFECTS; DRUG THERAPY; GENETICS; KNOCKOUT MOUSE; PSYCHOLOGY; WITHDRAWAL SYNDROME;

ALCOHOL DETERRENTS; ALCOHOL DRINKING; ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY; BEHAVIOR, ANIMAL; BENZAMIDES; DIAZEPAM; LIGANDS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; NALTREXONE; NARCOTIC ANTAGONISTS; PIPERAZINES; QUINOLINES; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RECEPTORS, OPIOID, DELTA; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 77957224441     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.110.170969     Document Type: Article

References (49)

1. Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, Gastfriend DR, Hosking JD, Johnson BA, LoCastro JS, et al. (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. JAMA 295:2003-2017.
2. Bie B, Zhu W, and Pan ZZ (2009) Ethanol-induced δ-opioid receptor modulation of glutamate synaptic transmission and conditioned place preference in central amygdala. Neuroscience 160:348-358.
3. Buonopane A and Petrakis IL (2005) Pharmacotherapy of alcohol use disorders. Subst Use Misuse 40:2001-2020, 2043-2048.
4. Cahill CM, Morinville A, Hoffert C, O'Donnell D, and Beaudet A (2003) Upregulation and trafficking of δ opioid receptor in a model of chronic inflammation: implications for pain control. Pain 101:199-208. (Pubitemid 36044668)
5. Cahill CM, Morinville A, Lee MC, Vincent JP, Collier B, and Beaudet A (2001) Prolonged morphine treatment targets δ opioid receptors to neuronal plasma membranes and enhances δ-mediated antinociception. J Neurosci 21:7598-7607. (Pubitemid 32904959)
6. Carola V, D'Olimpio F, Brunamonti E, Mangia F, and Renzi P (2002) Evaluation of the elevated plus-maze and open-field tests for the assessment of anxiety-related behavior in inbred mice. Behav Brain Res 134:49-57. (Pubitemid 34912685)
7. Ciccocioppo R, Martin-Fardon R, and Weiss F (2002) Effect of selective blockade of μ(1) or δ opioid receptors on reinstatement of alcohol-seeking behavior by drug-associated stimuli in rats. Neuropsychopharmacology 27:391-399. (Pubitemid 35256145)
8. Cloos JM and Ferreira V (2009) Current use of benzodiazepines in anxiety disorders. Curr Opin Psychiatry 22:90-95.
9. Commons KG (2003) Translocation of presynaptic δ opioid receptors in the ventrolateral periaqueductal gray after swim stress. J Comp Neurol 464:197-207.
10. Filliol D, Ghozland S, Chluba J, Martin M, Matthes HW, Simonin F, Befort K, Gavériaux-Ruff C, Dierich A, LeMeur M, et al. (2000) Mice deficient for δ- and μ-opioid receptors exhibit opposing alterations of emotional responses. Nat Genet 25:195-200.
11. Garbutt JC (2009) The state of pharmacotherapy for the treatment of alcohol dependence. J Subst Abuse Treat 36:S15-S23; quiz S24-S25.
12. George DT, Gilman J, Hersh J, Thorsell A, Herion D, Geyer C, Peng X, Kielbasa W, Rawlings R, Brandt JE, et al. (2008) Neurokinin 1 receptor antagonism as a possible therapy for alcoholism. Science 319:1536-1539.
13. Griebel G, Belzung C, Perrault G, and Sanger DJ (2000) Differences in anxiety-related behaviours and in sensitivity to diazepam in inbred and outbred strains of mice. Psychopharmacology (Berl) 148:164-170.
14. Heilig M, Thorsell A, Sommer WH, Hansson AC, Ramchandani VA, George DT, Hommer D, and Barr CS (2009) Translating the neuroscience of alcoholism into clinical treatments: from blocking the buzz to curing the blues. Neurosci Biobehav Rev doi:10.1016/j.neubiorev.2009.11.018.
15. Hoffman DL, Dukes EM, and Wittchen HU (2008) Human and economic burden of generalized anxiety disorder. Depress Anxiety 25:72-90.
16. Isbister GK, O'Regan L, Sibbritt D, and Whyte IM (2004) Alprazolam is relatively more toxic than other benzodiazepines in overdose. Br J Clin Pharmacol 58:88-95.
17. Kamei J, Ohsawa M, Suzuki T, Saitoh A, Endoh T, Narita M, Tseng LF, and Nagase H (1999) The modulatory effect of (+)-TAN-67 on the antinociceptive effects of the nociceptin/orphanin FQ in mice. Eur J Pharmacol 383:241-247.
18. King AC, Volpicelli JR, Gunduz M, O'Brien CP, and Kreek MJ (1997) Naltrexone biotransformation and incidence of subjective side effects: a preliminary study. Alcohol Clin Exp Res 21:906-909.
19. Kliethermes CL (2005) Anxiety-like behaviors following chronic ethanol exposure. Neurosci Biobehav Rev 28:837-850.
20. Knapp RJ, Landsman R, Waite S, Malatynska E, Varga E, Haq W, Hruby VJ, Roeske WR, Nagase H, and Yamamura HI (1995) Properties of TAN-67, a nonpeptidic δ-opioid receptor agonist, at cloned human δ- and μ-opioid receptors. Eur J Pharmacol 291:129-134.
21. Knapp RJ, Santoro G, De Leon IA, Lee KB, Edsall SA, Waite S, Malatynska E, Varga E, Calderon SN, Rice KC, et al. (1996) Structure-activity relationships for SNC80 and related compounds at cloned human δ and μ opioid receptors. J Pharmacol Exp Ther 277:1284-1291.
22. Kozak AT, Spates CR, McChargue DE, Bailey KC, Schneider KL, and Liepman MR (2007) Naltrexone renders one-session exposure therapy less effective: a controlled pilot study. J Anxiety Disord 21:142-152.
23. Lalonde R and Strazielle C (2008) Relations between open-field, elevated plus-maze, and emergence tests as displayed by C57/BL6J and BALB/c mice. J Neurosci Methods 171:48-52.
24. Lê AD, Poulos CX, Harding S, Watchus J, Juzytsch W, and Shaham Y (1999) Effects of naltrexone and fluoxetine on alcohol self-administration and reinstatement of alcohol seeking induced by priming injections of alcohol and exposure to stress. Neuropsychopharmacology 21:435-444.
25. Lepicard EM, Joubert C, Hagneau I, Perez-Diaz F, and Chapouthier G (2000) Differences in anxiety-related behavior and response to diazepam in BALB/cByJ and C57BL/6J strains of mice. Pharmacol Biochem Behav 67:739-748.
26. Liu X and Weiss F (2003) Stimulus conditioned to foot-shock stress reinstates alcohol-seeking behavior in an animal model of relapse. Psychopharmacology (Berl) 168:184-191.
27. Maremmani I, Marini G, and Fornai F (1998) Naltrexone-induced panic attacks. Am J Psychiatry 155:447.
28. Margolis EB, Fields HL, Hjelmstad GO, and Mitchell JM (2008) Delta-opioid receptor expression in the ventral tegmental area protects against elevated alcohol consumption. J Neurosci 28:12672-12681.
29. Marinelli PW, Funk D, Harding S, Li Z, Juzytsch W, and Lê AD (2009) Roles of opioid receptor subtypes in mediating alcohol-seeking induced by discrete cues and context. Eur J Neurosci 30:671-678.
30. Mattia A, Vanderah T, Mosberg HI, Omnaas JR, Bowen WD, and Porreca F (1991) Pharmacological characterization of [D-Ala2,Leu5,Ser6]enkephalin (DALES): antinociceptive actions at the δ noncomplexed-opioid receptor. Eur J Pharmacol 192:371-375.
31. McKeon A, Frye MA, and Delanty N (2008) The alcohol withdrawal syndrome. J Neurol Neurosurg Psychiatry 79:854-862.
32. Mitchell JM, Bergren LJ, Chen KS, Rowbotham MC, and Fields HL (2009) Naltrexone aversion and treatment efficacy are greatest in humans and rats that actively consume high levels of alcohol. Neurobiol Dis 33:72-80.
33. O'Brien CP (2005) Benzodiazepine use, abuse, and dependence. J Clin Psychiatry 66 (Suppl 2):28-33.
34. Perrine SA, Hoshaw BA, and Unterwald EM (2006) Delta opioid receptor ligands modulate anxiety-like behaviors in the rat. Br J Pharmacol 147:864-872.
35. Pettinati HM, Volpicelli JR, Pierce JD Jr, and O'Brien CP (2000) Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 19:71-83.
36. Primeaux SD, Wilson SP, McDonald AJ, Mascagni F, and Wilson MA (2006) The role of δ opioid receptors in the anxiolytic actions of benzodiazepines. Pharmacol Biochem Behav 85:545-554.
37. Ragnauth A, Schuller A, Morgan M, Chan J, Ogawa S, Pintar J, Bodnar RJ, and Pfaff DW (2001) Female preproenkephalin-knockout mice display altered emotional responses. Proc Natl Acad Sci USA 98:1958-1963.
38. Raynor K, Kong H, Chen Y, Yasuda K, Yu L, Bell GI, and Reisine T (1994) Pharmacological characterization of the cloned κ-, δ-, and μ-opioid receptors. Mol Pharmacol 45:330-334.
39. Roberts AJ, Gold LH, Polis I, McDonald JS, Filliol D, Kieffer BL, and Koob GF (2001) Increased ethanol self-administration in δ-opioid receptor knockout mice. Alcohol Clin Exp Res 25:1249-1256.
40. Saitoh A, Kimura Y, Suzuki T, Kawai K, Nagase H, and Kamei J (2004) Potential anxiolytic and antidepressant-like activities of SNC80, a selective δ-opioid agonist, in behavioral models in rodents. J Pharmacol Sci 95:374-380. (Pubitemid 39037898)
41. Saitoh A, Yoshikawa Y, Onodera K, and Kamei J (2005) Role of δ-opioid receptor subtypes in anxiety-related behaviors in the elevated plus-maze in rats. Psychopharmacology (Berl) 182:327-334. (Pubitemid 41464644)
42. Sanna E, Mostallino MC, Busonero F, Talani G, Tranquilli S, Mameli M, Spiga S, Follesa P, and Biggio G (2003) Changes in GABA(A) receptor gene expression associated with selective alterations in receptor function and pharmacology after ethanol withdrawal. J Neurosci 23:11711-11724.
43. Simon G (2001) Choosing a first-line antidepressant: equal on average does not mean equal for everyone. JAMA 286:3003-3004.
44. Söderpalm AH and Hansen S (1998) Benzodiazepines enhance the consumption and palatability of alcohol in the rat. Psychopharmacology (Berl) 137:215-222.
45. Swift R (2007) Emerging approaches to managing alcohol dependence. Am J Health Syst Pharm 64:S12-S22.
46. Tiwari AK, Souza RP, and Müller DJ (2009) Pharmacogenetics of anxiolytic drugs. J Neural Transm 116:667-677.
47. van Rijn RM and Whistler JL (2009) The δ(1) opioid receptor is a heterodimer that opposes the actions of the δ(2) receptor on alcohol intake. Biol Psychiatry 66:777-784.
48. Wittchen HU (2002) Generalized anxiety disorder: prevalence, burden, and cost to society. Depress Anxiety 16:162-171.
49. Zaki PA, Bilsky EJ, Vanderah TW, Lai J, Evans CJ, and Porreca F (1996) Opioid receptor types and subtypes: the δ receptor as a model. Annu Rev Pharmacol Toxicol 36:379-401.